OptimizeRx (NASDAQ:OPRX) Now Covered by Stephens

Stephens started coverage on shares of OptimizeRx (NASDAQ:OPRX) in a report released on Friday, Marketbeat.com reports. The brokerage issued an equal weight rating and a $5.50 price objective on the stock.

Other equities analysts also recently issued reports about the stock. Stifel Nicolaus decreased their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Barclays cut their price objective on shares of OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, November 14th. JMP Securities lowered their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating on the stock in a report on Thursday, November 14th. Finally, Royal Bank of Canada reduced their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $9.71.

OptimizeRx Trading Up 3.4 %

Shares of OptimizeRx stock opened at $4.91 on Friday. The stock has a market cap of $90.45 million, a P/E ratio of -3.69 and a beta of 1.34. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65. The business’s 50 day moving average is $5.41 and its 200-day moving average is $7.87.

Insiders Place Their Bets

In other news, CEO William J. Febbo purchased 20,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at $3,012,277.53. This trade represents a 3.44 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On OptimizeRx

A number of hedge funds have recently modified their holdings of OPRX. Barclays PLC grew its position in shares of OptimizeRx by 358.5% in the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares during the last quarter. Bullseye Asset Management LLC increased its position in shares of OptimizeRx by 55.6% during the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock worth $1,652,000 after buying an additional 76,458 shares during the period. BNP Paribas Financial Markets lifted its holdings in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after buying an additional 2,414 shares during the period. Quest Partners LLC boosted its position in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after acquiring an additional 9,739 shares during the last quarter. Finally, Greenwood Capital Associates LLC grew its holdings in OptimizeRx by 8.0% during the 3rd quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares during the period. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.